

**Amendments to the Claims**

Following is the current listing of claims. This listing of claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) A selective antagonist to denatured collagen type-IV selective peptide antagonist wherein said antagonist is a peptide comprising a core amino acid sequence SEQ ID NO. 1: L-K-Q-N-G-G-N-F-S-L.
- 3-5. (Canceled)
6. (Currently Amended) The antagonist of claim 2 wherein the binding affinity of the ~~denatured collagen type-IV selective antagonist~~ to denatured type-IV collagen is substantially greater than the binding affinity of said antagonist to native collagen type-IV.
7. (Currently Amended) The antagonist of claim 2 wherein the binding affinity of the ~~selective denatured collagen type-IV antagonist~~ to denatured type-IV collagen is 100-fold greater than the binding affinity of said antagonist to native collagen.
8. (Currently Amended) The antagonist of claim 2 wherein the ~~selective denatured collagen type-IV antagonist~~ inhibits cellular interaction with denatured collagen type-IV.
9. (Currently Amended) A pharmaceutical composition comprising an a selective ~~denatured collagen type-IV antagonist~~ according to Claim 2 and a pharmaceutically acceptable excipient.
10. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytotoxic agent.
11. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a radioactive material.
12. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytostatic agent.
- 13-37. (Canceled)

Serial No.: 10/782,728  
Filed: February 18, 2004

**P A T E N T**  
*WSGR Reference No. 31747-705.201*

38. (New) An antagonist selective for denatured collagen type-IV, wherein said antagonist is a polypeptide comprising a core amino acid sequence SEQ ID NO. 1: L-K-Q-N-G-G-N-F-S-L.